CLINICAL TRIALS PROFILE FOR DEUTETRABENAZINE
✉ Email this page to a colleague
All Clinical Trials for Deutetrabenazine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01795859 ↗ | First Time Use of SD-809 in Huntington Disease | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | 2013-08-05 | The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease. |
| NCT01795859 ↗ | First Time Use of SD-809 in Huntington Disease | Completed | Teva Pharmaceutical Industries | Phase 3 | 2013-08-05 | The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease. |
| NCT01897896 ↗ | Alternatives for Reducing Chorea in Huntington Disease | Completed | Auspex Pharmaceuticals, Inc. | Phase 3 | 2013-11-12 | The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER. |
| NCT02195700 ↗ | Aim to Reduce Movements in Tardive Dyskinesia | Completed | Auspex Pharmaceuticals, Inc. | Phase 2/Phase 3 | 2014-06-01 | The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia. |
| NCT02198794 ↗ | Reducing Involuntary Movements in Participants With Tardive Dyskinesia | Completed | Auspex Pharmaceuticals, Inc. | Phase 3 | 2014-10-20 | The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809. |
| NCT02291861 ↗ | Addressing Involuntary Movements in Tardive Dyskinesia | Completed | Auspex Pharmaceuticals, Inc. | Phase 3 | 2014-10-31 | The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Deutetrabenazine
Condition Name
Clinical Trial Locations for Deutetrabenazine
Trials by Country
Clinical Trial Progress for Deutetrabenazine
Clinical Trial Phase
Clinical Trial Sponsors for Deutetrabenazine
Sponsor Name
